Veralto Corp, founded in 2022 and headquartered in the United States, is dedicated to providing innovative solutions in the life sciences sector. The company specializes in advanced instrumentation and software that facilitate data analysis and enhanced laboratory workflows.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| VLTO 4.15% 2031-09-19 EURVeralto Corp | United States | 2031-09-19 | 4.150 | 3.35 |
| VLTO 4.15% 2031-09-19 EURVeralto Corp | United States | 2031-09-19 | 4.150 | 3.35 |
| VLTO 4.15% 2031-09-19 EURVeralto Corp | United States | 2031-09-19 | 4.150 | 3.35 |
| VLTO 5.35% 2028-09-18 USDVeralto Corp | United States | 2028-09-18 | 5.350 | 4.45 |
| VLTO 5.35% 2028-09-18 USDVeralto Corp | United States | 2028-09-18 | 5.350 | 4.45 |
| VLTO 5.35% 2028-09-18 USDVeralto Corp | United States | 2028-09-18 | 5.350 | 4.05 |
| VLTO 5.45% 2033-09-18 USDVeralto Corp | United States | 2033-09-18 | 5.450 | 3.94 |
| VLTO 5.45% 2033-09-18 USDVeralto Corp | United States | 2033-09-18 | 5.450 | 3.94 |
| VLTO 5.50% 2026-09-18 USDVeralto Corp | United States | 2026-09-18 | 5.500 | 4.24 |
| VLTO 5.50% 2026-09-18 USDVeralto Corp | United States | 2026-09-18 | 5.500 | 4.24 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Since the launch of its bond program in 2023, Veralto Corp has issued several notable bonds, including a $500 million offering that garnered significant investor interest due to its competitive yield of 3.5%, well above the industry average. This initial issuance was strategically aimed at funding research and development initiatives. As of the latest update, the company continues to display strong creditworthiness, with positive projections regarding both its financial stability and growth trajectory, making its bonds an appealing option for retail investors.